{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"46"},{"groupId":"OG002","value":"49"}]}],"title":"Any AE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"25"},{"groupId":"OG002","value":"22"}]}],"title":"Any SAE"}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"46"},{"groupId":"OG002","value":"49"}],"units":"Participants"}],"description":"A summary of other nonserious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section.","groups":[{"description":"Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.\n\nDocetaxel: 75 mg/m2 on Day 1 of each 21-day cycle","id":"OG000","title":"Docetaxel"},{"description":"Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.\n\nDocetaxel: 75 mg/m2 on Day 1 of each 21-day cycle\n\nRamucirumab (DP): 10 mg/kg IV on day 1 of each 21-day cycle","id":"OG001","title":"Docetaxel + Ramucirumab DP"},{"description":"Cycles repeat every 3 weeks until disease Progression, unacceptable toxicity, or withdrawal.\n\nDocetaxel: 75 mg/m2 on Day 1 of each 21-day cycle\n\nIcrucumab: 12 mg/kg IV on day 1 and Day 8 of each 21-day cycle","id":"OG002","title":"Docetaxel + Icrucumab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All randomized participants who received at least one dose of study drug.","reportingStatus":"POSTED","timeFrame":"Up To 41.7 Months","title":"Number of Participants With Adverse Events (AEs)","type":"SECONDARY","unitOfMeasure":"Participants"}